title: Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
abstract: The use of single-chain variable fragment (scFv) constructs has been investigated in cancer radioimmunotherapy (RIT) and radioimmunodetection, as these molecules permit rapid tumor penetration and clearance from the serum relative to whole IgG. Multimerization of scFv constructs has demonstrated improvements in functional affinity (i.e., avidity) and maximal tumor uptake. In this paper, we report the first biodistribution and pharmacokinetics studies of a noncovalent, direct-linked scFv (V(L)-0-V(H)) trimeric/tetrameric "multimer" of the anti-Lewis Y monoclonal antibody, hu3S193. The in vitro binding and in vivo biodistribution of the hu3S193 multimer was characterized alongside the hu3S193 F(ab')(2) following radiolabeling with the Indium-111 ((111)In) radioisotope. Immunoreactivities of the radiolabeled multimer and F(ab')(2) were 73% and 53.2%, and binding affinities (K(a)) were 1.58 x 10(7) M(1) and 4.31 x 10(6) M (1) for the multimer and F(ab')(2), respectively. Maximal tumor uptake in Le(y)-positive MCF-7 breast cancer xenografted BALB/c nude mice was 12.6 +/- 2.5 percent injected dose/per gram (%ID/g) at 6 hours postinjection for the multimer and 15.7 +/- 2.1 %ID/g at 24 hours postinjection for the F(ab')(2). However, limited in vitro stability and high renal localization of radiolabeled constructs were observed, which, despite the observed tumor targeting of the hu3S193 multimer, most likely preclude its use in RIT and imaging modalities.
authors.affiliation: Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia.
authors.forename: Marcus P
authors.initials: MP
authors.lastname: Kelly
authors.forename: F-T
authors.initials: FT
authors.lastname: Lee
authors.forename: Kiki
authors.initials: K
authors.lastname: Tahtis
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Power
authors.forename: Fiona E
authors.initials: FE
authors.lastname: Smyth
authors.forename: Martin W
authors.initials: MW
authors.lastname: Brechbiel
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Hudson
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Scott
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics; D061067:Antibodies, Monoclonal, Humanized; D019540:Area Under Curve; D045744:Cell Line, Tumor; D002850:Chromatography, Gel; D004355:Drug Stability; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000097:blood / Q000493:pharmacokinetics*; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007205:Indium Radioisotopes; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000378:metabolism*; D011877:Radionuclide Imaging; D011994:Recombinant Proteins / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C522039:Hu3S193 monoclonal antibody; D018796:Immunoconjugates; D007140:Immunoglobulin Fab Fragments; D007135:Immunoglobulin Variable Region; D007205:Indium Radioisotopes; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen; D011994:Recombinant Proteins
references.citation: Clin Cancer Res. 2001 Jan;7(1):175-84
references.pmid: 11205906
references.citation: Nat Rev Immunol. 2006 May;6(5):343-57
references.pmid: 16622479
references.citation: Protein Sci. 1997 Apr;6(4):781-8
references.pmid: 9098887
references.citation: Cancer Res. 1996 May 1;56(9):2123-9
references.pmid: 8616860
references.citation: J Nucl Med. 2006 Apr;47(4):716-25
references.pmid: 16595507
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1550-8
references.pmid: 16818514
references.citation: J Nucl Med. 1993 Oct;34(10):1728-38
references.pmid: 8410290
references.citation: J Immunol Methods. 2001 Feb 1;248(1-2):47-66
references.pmid: 11223068
references.citation: Curr Opin Struct Biol. 1998 Aug;8(4):443-50
references.pmid: 9729735
references.citation: Protein Eng Des Sel. 2004 Jan;17(1):21-7
references.pmid: 14985534
references.citation: Nat Biotechnol. 2003 Dec;21(12):1486-92
references.pmid: 14634668
references.citation: Nucl Med Biol. 1995 Apr;22(3):387-90
references.pmid: 7627155
references.citation: Int J Cancer. 1997 Sep 26;73(1):50-6
references.pmid: 9334809
references.citation: J Mol Biol. 2005 Apr 8;347(4):773-89
references.pmid: 15769469
references.citation: J Nucl Med. 2005 Jan;46 Suppl 1:115S-27S
references.pmid: 15653660
references.citation: J Mol Biol. 1997 Apr 25;268(1):107-17
references.pmid: 9149145
references.citation: Bioorg Med Chem. 1997 Oct;5(10):1925-34
references.pmid: 9370037
references.citation: J Immunol Methods. 2000 Aug 28;242(1-2):193-204
references.pmid: 10986400
references.citation: Cancer Res. 1999 Jan 1;59(1):128-34
references.pmid: 9892197
references.citation: Int J Cancer. 1997 Jul 29;72(3):522-9
references.pmid: 9247299
references.citation: Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):657-70
references.pmid: 16828920
references.citation: Cancer Res. 2000 Jun 15;60(12):3254-61
references.pmid: 10866319
references.citation: Nat Biotechnol. 2005 Sep;23(9):1126-36
references.pmid: 16151406
references.citation: Nat Biotechnol. 2005 Sep;23(9):1137-46
references.pmid: 16151407
references.citation: Int J Cancer. 2004 Nov 10;112(3):509-18
references.pmid: 15382079
references.citation: Cancer Res. 1995 Sep 1;55(17):3825-34
references.pmid: 7641200
references.citation: Nat Med. 2003 Jan;9(1):129-34
references.pmid: 12514726
references.citation: Nucl Med Biol. 2005 Feb;32(2):157-64
references.pmid: 15721761
references.citation: Int Immunopharmacol. 2006 May;6(5):791-9
references.pmid: 16546710
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3286-92
references.pmid: 17545534
references.citation: Nucl Med Biol. 1995 May;22(4):413-23
references.pmid: 7550017
references.citation: Protein Eng Des Sel. 2004 Apr;17(4):357-66
references.pmid: 15126676
references.citation: Cancer Res. 2000 Dec 15;60(24):6964-71
references.pmid: 11156397
references.citation: Clin Cancer Res. 2001 Apr;7(4):1061-72
references.pmid: 11309358
references.citation: J Immunol Methods. 2004 Jun;289(1-2):65-80
references.pmid: 15251413
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4810-7
references.pmid: 16000578
references.citation: Cancer Treat Res. 1990;51:153-71
references.pmid: 1977442
references.citation: J Nucl Med. 2005 Jun;46(6):1012-5
references.pmid: 15937313
references.citation: Protein Sci. 2003 Apr;12(4):734-47
references.pmid: 12649432
references.citation: Biomol Eng. 2001 Oct 15;18(3):95-108
references.pmid: 11566601
references.citation: Biochem Biophys Res Commun. 2005 Feb 25;327(4):999-1005
references.pmid: 15652494
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s
references.pmid: 16203810
references.citation: Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s
references.pmid: 10541342
references.citation: J Immunol Methods. 1999 Dec 10;231(1-2):249-60
references.pmid: 10648942
references.citation: Curr Opin Biotechnol. 2002 Dec;13(6):603-8
references.pmid: 12482521
references.citation: J Nucl Med. 2001 Oct;42(10):1519-27
references.pmid: 11585867
references.citation: Q J Nucl Med Mol Imaging. 2004 Dec;48(4):279-88
references.pmid: 15640791
references.citation: Cancer Res. 2000 Sep 1;60(17):4804-11
references.pmid: 10987290
references.citation: Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):264-73
references.pmid: 15791435